Skip to main content

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Learn more about the latest Signatera™ data in high-risk breast cancer:

Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring during neoadjuvant therapy Updates from recent conferences highlighting how ctDNA-based MRD testing may inform adjuvant treatment decisions Patient case studies demonstrating the utility of Signatera™ testing across the breast cancer treatment continuum